Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Allison B Goldfine"'
Autor:
Charlotte Hagman, Gaetan Chasseigne, Robert Nelson, Florian Anlauff, Mark Kagan, Allison B. Goldfine, Grzegorz Terszowski, Maria Jadhav
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The clinical immunogenicity assessment for complex multidomain biological drugs is challenging due to multiple factors that must be taken into consideration. Here, we describe a strategy to overcome multiple bioanalytical challenges in order to asses
Externí odkaz:
https://doaj.org/article/7b5a650d46c844bcaf6b7b4b75ba816c
Autor:
Jeffrey Kennedy, Hitoshi Katsuta, Min-Ho Jung, Lorella Marselli, Allison B Goldfine, Ulysses J Balis, Dennis Sgroi, Susan Bonner-Weir, Gordon C Weir
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e11211 (2010)
There is great interest about the possible contribution of ER stress to the apoptosis of pancreatic beta cells in the diabetic state and with islet transplantation.Expression of genes involved in ER stress were examined in beta cell enriched tissue o
Externí odkaz:
https://doaj.org/article/dd7b6ae8179c472997d3dcdb56caf52a
Publikováno v:
Frontiers in Clinical Diabetes and Healthcare, Vol 4 (2023)
IntroductionContinuous glucose monitoring (CGM) devices capture longitudinal data on interstitial glucose levels and are increasingly used to show the dynamics of diabetes metabolism. Given the complexity of CGM data, it is crucial to extract importa
Externí odkaz:
https://doaj.org/article/0b9d0c6469524d3d96058b394533bb20
Autor:
Jill Kompa, Doug Hom, Markus Hinder, John L. Diener, Daniel J. Rader, Allison B Goldfine, Amanda Nguyen, Craig T. Basson, Miljen Martic, David Yowe, Cllf X study team, Eleftheria Maratos-Flier, Yifang Li, Michael Ferriere
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:e57-e70
Purpose To evaluate the safety and potential efficacy of LLF580, a genetically engineered variant of human fibroblast growth factor-21, for triglyceride lowering, weight loss, and hepatic fat reduction. Methods A multicenter, double-blind, parallel d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::433704e32ab2abea81879ec8f81a250b
https://doi.org/10.1210/clinem/dgab624
https://doi.org/10.1210/clinem/dgab624
Autor:
John P. Kirwan, Anita P. Courcoulas, David E. Cummings, Allison B. Goldfine, Sangeeta R. Kashyap, Donald C. Simonson, David E. Arterburn, William F. Gourash, Ashley H. Vernon, John M. Jakicic, Mary Elizabeth Patti, Kathy Wolski, Philip R. Schauer
OBJECTIVE The overall aim of the Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) consortium is to assess the durability and longer-term effectiveness of metabolic surgery compared with medical/lifesty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f91f0757e0aeb7752eaacb4a50d7f86b
https://doi.org/10.2337/figshare.19237437.v1
https://doi.org/10.2337/figshare.19237437.v1
Autor:
J. S. Haw, Michael Mauer, Janet B. McGill, Jill P. Crandall, Bruce A. Perkins, Ruth S. Weinstock, Katherine R. Tuttle, Afshin Parsa, Tom Elliott, Peter Rossing, Amy B. Karger, Amisha Wallia, Cathie Spino, Mark E. Molitch, I. H. de Boer, Maryam Afkarian, David Z.I. Cherney, Sylvia E. Rosas, Irl B. Hirsch, Sarit Polsky, Allison B. Goldfine, Andrzej T. Galecki, Guillermo E. Umpierrez, Ronald J. Sigal, Marlon Pragnell, Ildiko Lingvay, M. L. Caramori, Rodica Pop-Busui, Ronnie Aronson, William N. Robiner, Chun Yi Wu, David M. Maahs, Peter A. Senior, Alessandro Doria
Publikováno v:
N Engl J Med
BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6ef2b59ae2513d4a7415a3b5af846c
https://doi.org/10.1056/nejmoa1916624
https://doi.org/10.1056/nejmoa1916624
Autor:
Bela F. Asztalos, Thomas H. Hauser, Allison B. Goldfine, Francine K. Welty, Katalin V. Horvath, Ernst J. Schaefer
Publikováno v:
Atherosclerosis. 345
The regulation of cell-cholesterol efflux is not completely understood. Our aim was to assess the role of HDL- and non-HDL-related parameters in ATP-binding cassette transporter-A1 (ABCA1) and scavenger receptor class B-type-I (SRBI) cell-cholesterol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85bad2eed030d780d58960003b692a3b
https://pubmed.ncbi.nlm.nih.gov/35183903
https://pubmed.ncbi.nlm.nih.gov/35183903
Autor:
Amisha Wallia, Irl B. Hirsch, Afshin Parsa, Alessandro Doria, J. Sonya Haw, Catherine Spino, Bruce A. Perkins, Amy B. Karger, Peter Rossing, Katherine R. Tuttle, Andrzej T. Galecki, Ruth S. Weinstock, Rodica Pop-Busui, Sylvia E. Rosas, Guillermo E. Umpierrez, Ronald J. Sigal, David M. Maahs, Ildiko Lingvay, Janet B. McGill, Maryam Afkarian, Jill P. Crandall, Mark E. Molitch, Ronnie Aronson, Peter A. Senior, Allison B. Goldfine, Sarit Polsky, Michael Mauer, Maria Luiza Caramori, David Z.I. Cherney, Chun Yi Wu, Ian H. de Boer, Marlon Pragnell, Tom Elliott
Publikováno v:
Diabetes Care
OBJECTIVE Higher serum uric acid (SUA) is associated with diabetic kidney disease (DKD). Preventing Early Renal Loss in Diabetes (PERL) evaluates whether lowering SUA with allopurinol slows glomerular filtration rate (GFR) loss in people with type 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161069f67a494d7d13a9306f23733ed4
https://doi.org/10.2337/dc19-0342
https://doi.org/10.2337/dc19-0342
Autor:
Angela Tong, Chintan V. Dave, Elisabetta Patorno, Allison B. Goldfine, Seoyoung C. Kim, Robert J. Glynn
Publikováno v:
Circulation. 143(8)
Background: Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in type 2 diabetes in large randomized controlled trials in patients with establishe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918f38bdf28a8a4261e8be3b2b2a877d
https://pubmed.ncbi.nlm.nih.gov/33617317
https://pubmed.ncbi.nlm.nih.gov/33617317
Publikováno v:
Diabetes. 69
SGLT2 inhibitors (SGLT2i) may provide cardiovascular (CV) benefit when added to GLP-1 receptor agonists (GLP-1RA) given the orthogonal mechanisms of action, although combined use is incompletely understood. Patients adding either SGLT2i or sulfonylur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10906a88021212e46047dcfd132665de
https://doi.org/10.2337/db20-35-or
https://doi.org/10.2337/db20-35-or